Avalo Therapeutics' Lead Drug now a Cleaner Immunology Story, BofA Says

MT Newswires Live06-12 23:00

Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said in a Friday research report.

The results offer the pathway to relatively superior disease impact if consistency is retained in phase 3 studies starting H1 2027, BofA said.

The brokerage said its investment case is founded on the company's differentiated IL-1Beta antibody for the inflammatory skin disease, a massive undertreated market, and a balance sheet runway through next major data readout in 2029.

Avalo's reliance on a single asset as well as variability in placebo responses in hidradenitis suppurativa studies continue to pose key risks, according to the note.

The brokerage said it initiated coverage of the stock with a buy rating and a price target of $35 per share.

Price: 14.39, Change: +0.72, Percent Change: +5.23

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642299231?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642299231","market":"sh","top_or_hot":-1,"title":"Avalo Therapeutics' Lead Drug now a Cleaner Immunology Story, BofA Says","media":"MT Newswires Live","content":"<html><body><p> Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said in a Friday research report.</p><p>The results offer the pathway to relatively superior disease impact if consistency is retained in phase 3 studies starting H1 2027, BofA said.</p><p>The brokerage said its investment case is founded on the company's differentiated IL-1Beta antibody for the inflammatory skin disease, a massive undertreated market, and a balance sheet runway through next major data readout in 2029.</p><p>Avalo's reliance on a single asset as well as variability in placebo responses in hidradenitis suppurativa studies continue to pose key risks, according to the note.</p><p>The brokerage said it initiated coverage of the stock with a buy rating and a price target of $35 per share.</p><p>Price: 14.39, Change: +0.72, Percent Change: +5.23</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avalo Therapeutics' Lead Drug now a Cleaner Immunology Story, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvalo Therapeutics' Lead Drug now a Cleaner Immunology Story, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-12 23:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said in a Friday research report.</p><p>The results offer the pathway to relatively superior disease impact if consistency is retained in phase 3 studies starting H1 2027, BofA said.</p><p>The brokerage said its investment case is founded on the company's differentiated IL-1Beta antibody for the inflammatory skin disease, a massive undertreated market, and a balance sheet runway through next major data readout in 2029.</p><p>Avalo's reliance on a single asset as well as variability in placebo responses in hidradenitis suppurativa studies continue to pose key risks, according to the note.</p><p>The brokerage said it initiated coverage of the stock with a buy rating and a price target of $35 per share.</p><p>Price: 14.39, Change: +0.72, Percent Change: +5.23</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642299231","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642299231","pubTimestamp":1781276427,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Avalo Therapeutics'  lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said in a Friday research report.The results offer the pathway to relatively superior disease impact if consistency is retained in phase 3 studies starting H1 2027, BofA said.The brokerage said its investment case is founded on the company's differentiated IL-1Beta antibody for the inflammatory skin disease, a massive undertreated market, and a balance sheet runway through next major data readout in 2029.Avalo's reliance on a single asset as well as variability in placebo responses in hidradenitis suppurativa studies continue to pose key risks, according to the note.The brokerage said it initiated coverage of the stock with a buy rating and a price target of $35 per share.Price: 14.39, Change: +0.72, Percent Change: +5.23","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","DBB":"基础金属ETF-PowerShares","BK4007":"制药","BK4539":"次新股","AVTX":"Avalo Therapeutics Inc","BK4139":"生物科技"},"translate_title":"美国银行表示，Avalo Therapeutics的主导药物现在是一个更干净的免疫学故事","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVTX":1,"LENZ":1.5,"DBB":1.5},"content_text":"Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said in a Friday research report.The results offer the pathway to relatively superior disease impact if consistency is retained in phase 3 studies starting H1 2027, BofA said.The brokerage said its investment case is founded on the company's differentiated IL-1Beta antibody for the inflammatory skin disease, a massive undertreated market, and a balance sheet runway through next major data readout in 2029.Avalo's reliance on a single asset as well as variability in placebo responses in hidradenitis suppurativa studies continue to pose key risks, according to the note.The brokerage said it initiated coverage of the stock with a buy rating and a price target of $35 per share.Price: 14.39, Change: +0.72, Percent Change: +5.23","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642299231","isCrawlerRequest":true}